Alimera Sciences\/EyePoint Pharma’s YUTIQ (fluocinolone acetonide) Overview<\/b><\/p>\n
YUTIQ is a sterile, non-biodegradable intravitreal implant containing 0.18 mg of fluocinolone acetonide (FA). It provides a sustained drug release at an initial rate of 0.25 \u00b5g per day over 36 months. This corticosteroid-based therapy is indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. The implant is preloaded in a single-use applicator for direct injection into the vitreous cavity. It received FDA approval in October 2018 and was commercially launched in the U.S. in February 2019.<\/p>\n
YUTIQ was developed to enhance the performance of RETISERT by delivering a lower corticosteroid dose to the retina, thereby reducing the incidence of adverse effects such as increased intraocular pressure (IOP) and cataract formation. Its extended duration of action also minimizes the need for frequent dosing, improving patient convenience and treatment tolerability.<\/p>\n
Drug Name<\/b><\/p>\n<\/td>\n
YUTIQ (fluocinolone acetonide)<\/b><\/p>\n<\/td>\n<\/tr>\n Molecule type<\/b><\/p>\n<\/td>\n Small molecule<\/p>\n<\/td>\n<\/tr>\n Developer<\/b><\/p>\n<\/td>\n Alimera Sciences\/EyePoint Pharma<\/p>\n<\/td>\n<\/tr>\n Year of approval<\/b><\/p>\n<\/td>\n US: 2018<\/p>\n Japan: 2022<\/p>\n<\/td>\n<\/tr>\n Target patient population<\/b><\/p>\n<\/td>\n Chronic NIU Affecting the Posterior Segment of the Eye<\/p>\n<\/td>\n<\/tr>\n Mechanism of action<\/b><\/p>\n<\/td>\n Anti-inflammatory<\/p>\n<\/td>\n<\/tr>\n Route of administration<\/b><\/p>\n<\/td>\n Intravitreal implant<\/p>\n<\/td>\n<\/tr>\n Learn more about YUTIQ projected market size for uveitis @ YUTIQ Market Potential<\/a><\/b>\u00a0<\/p>\n Uveitis is a rare condition characterized by inflammation in part or all of the uvea, the middle layer of the eye that includes the choroid, ciliary body, and iris. This inflammation can also impact other parts of the eye, such as the lens, retina, optic nerve, and vitreous humor. Uveitis represents a broad spectrum of inflammatory eye disorders and may result from trauma, infections, tumors, or autoimmune and inflammatory diseases. According to DelveInsight, there were approximately 1 million<\/b> diagnosed prevalent cases of uveitis across the 7MM in 2023, with numbers projected to rise between 2020 and 2034.<\/p>\n The primary objective of uveitis treatment is to control inflammation quickly, alleviate pain, and prevent vision loss and other complications. Current clinical guidelines stress the importance of early detection and timely intervention. Approved therapies include XIPERE, OZURDEX, HUMIRA, YUTIQ\/ILUVIEN, RETISERT, and DUREZOL<\/b>. The uveitis market in the 7MM was valued at around USD 1.54 billion<\/b> in 2023, and it is anticipated to grow further by 2034, driven by rising disease prevalence, enhanced understanding of its underlying mechanisms, and ongoing technological advancements.<\/p>\n Discover more about the uveitis\u00a0market in detail @ Uveitis Market Report<\/a><\/b><\/p>\n Emerging Competitors of YUTIQ<\/b><\/p>\n Prominent players such as Tarsier Pharma <\/b>with TRS01, Eli Lilly and Company<\/b> with OLUMIANT (baricitinib), Oculis Pharma<\/b> with licaminlimab (OCS-02), Priovant Therapeutics<\/b> with brepocitinib, and others are actively developing therapies for uveitis.<\/p>\n In September 2024, Brepocitinib<\/b> was granted Fast Track Designation (FTD) for NIU by the FDA for the treatment of non-anterior NIU. Fast track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.<\/p>\n In January 2024, Tarsier Pharma<\/b> received US FDA agreement under a Special Protocol Assessment (SPA) for the Phase III Tarsier-04 trial protocol and planned statistical analysis for evaluating TRS01 eye drops in treating non-infectious uveitis, including uveitic glaucoma.<\/p>\n To know more about the number of competing drugs in development, visit @ YUTIQ Market Positioning Compared to Other Drugs<\/a><\/b><\/p>\n Key Milestones of YUTIQ<\/b><\/p>\n Discover how YUTIQ is shaping the uveitis treatment landscape @ YUTIQ Injection<\/a><\/b><\/p>\n YUTIQ Market Dynamics<\/b><\/p>\n YUTIQ, an intravitreal fluocinolone acetonide implant developed by EyePoint Pharmaceuticals, is designed for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The market dynamics for YUTIQ are shaped by several key factors, including the rising prevalence of uveitis globally,<\/b> the unmet need for long-term treatment options<\/b>, and YUTIQ’s unique positioning<\/b> as a sustained-release corticosteroid implant that provides up to three years of continuous drug delivery.\u00a0<\/p>\n This extended-release capability differentiates it from other corticosteroid therapies<\/b>, which often require more frequent injections and carry higher systemic side effect risks. These features have helped YUTIQ carve out a niche<\/b>, especially among ophthalmologists and retinal specialists managing patients with recurrent or refractory uveitis.<\/p>\n However, market penetration for YUTIQ also faces several headwinds. Cost remains a significant barrier<\/b>, particularly in markets where reimbursement is limited or slow to be adopted. The presence of competing therapies, such as OZURDEX (dexamethasone intravitreal implant) and systemic immunosuppressive treatments<\/b>, also affects uptake.\u00a0<\/p>\n Furthermore, given the chronic nature of uveitis<\/b> and the relatively limited patient population<\/b>, growth is inherently capped by the size of the addressable market. Nonetheless, EyePoint’s efforts to expand payer coverage<\/b> and build stronger relationships<\/b> with retina specialists continue to support gradual market expansion. Overall, while YUTIQ addresses a critical clinical need, its long-term commercial success will depend on navigating access challenges and differentiating further from both systemic and local therapies.<\/p>\n Dive deeper to get more insight into YUTIQ’s strengths & weaknesses relative to competitors @ YUTIQ Market Drug Report<\/a><\/b><\/p>\n Table of Contents<\/b><\/p>\n 1<\/p>\n<\/td>\n Report Introduction<\/p>\n<\/td>\n<\/tr>\n 2<\/p>\n<\/td>\n YUTIQ: Alimera Sciences\/EyePoint Pharma<\/p>\n<\/td>\n<\/tr>\n 2.1<\/p>\n<\/td>\n Product Overview<\/p>\n<\/td>\n<\/tr>\n 2.2<\/p>\n<\/td>\n Other Development Activities<\/p>\n<\/td>\n<\/tr>\n 2.3<\/p>\n<\/td>\n Clinical Development<\/p>\n<\/td>\n<\/tr>\n 2.4<\/p>\n<\/td>\n Clinical Trials Information<\/p>\n<\/td>\n<\/tr>\n 2.5<\/p>\n<\/td>\n Safety and Efficacy<\/p>\n<\/td>\n<\/tr>\n 2.6<\/p>\n<\/td>\n Product Profile<\/p>\n<\/td>\n<\/tr>\n 2.7<\/p>\n<\/td>\n Market Assessment<\/p>\n<\/td>\n<\/tr>\n 2.7.1<\/p>\n<\/td>\n The 7MM Analysis<\/p>\n<\/td>\n<\/tr>\n 2.7.1.1<\/p>\n<\/td>\n Cost Assumptions and Rebate<\/p>\n<\/td>\n<\/tr>\n 2.7.1.2<\/p>\n<\/td>\n Pricing Trends<\/p>\n<\/td>\n<\/tr>\n 2.7.1.3<\/p>\n<\/td>\n Analogue Assessment<\/p>\n<\/td>\n<\/tr>\n 2.7.1.4<\/p>\n<\/td>\n Launch Year and Therapy Uptake<\/p>\n<\/td>\n<\/tr>\n 2.7.2<\/p>\n<\/td>\n The United States Market Analysis<\/p>\n<\/td>\n<\/tr>\n 2.7.3<\/p>\n<\/td>\n EU4 and the United Kingdom Market Analysis<\/p>\n<\/td>\n<\/tr>\n 2.7.3.1<\/p>\n<\/td>\n Germany<\/p>\n<\/td>\n<\/tr>\n 2.7.3.2<\/p>\n<\/td>\n France<\/p>\n<\/td>\n<\/tr>\n 2.7.3.3<\/p>\n<\/td>\n Italy<\/p>\n<\/td>\n<\/tr>\n 2.7.3.4<\/p>\n<\/td>\n Spain<\/p>\n<\/td>\n<\/tr>\n 2.7.3.5<\/p>\n<\/td>\n UK<\/p>\n<\/td>\n<\/tr>\n 2.7.4<\/p>\n<\/td>\n Japan Market Analysis<\/p>\n<\/td>\n<\/tr>\n 2.8<\/p>\n<\/td>\n Market Drivers<\/p>\n<\/td>\n<\/tr>\n 2.9<\/p>\n<\/td>\n Market Barriers<\/p>\n<\/td>\n<\/tr>\n 2.10<\/p>\n<\/td>\n SWOT Analysis<\/p>\n<\/td>\n<\/tr>\n 3<\/p>\n<\/td>\n Key Cross of Marketed Competitors of YUTIQ<\/p>\n<\/td>\n<\/tr>\n 4<\/p>\n<\/td>\n Key Cross of Emerging Competitors of YUTIQ<\/p>\n<\/td>\n<\/tr>\n Related Reports<\/b><\/p>\n Uveitis Market<\/a><\/b><\/p>\n Uveitis Market Insights, Epidemiology, and Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key uveitis\u00a0companies, including Tarsier Pharma, Oculis Pharma, Roche, Eli Lilly and Company, Acelyrin, Affibody Medical, Eyevensys, Priovant Therapeutics, Inc, Santen Inc., ABIONYX Pharma, OKYO Pharma,<\/b> among others.<\/p>\n Uveitis Pipeline<\/a><\/b><\/p>\n Uveitis Pipeline Insight \u2013 2025<\/b>\u00a0report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key\u00a0uveitis\u00a0companies, including Eli Lilly and Company, Santen Inc., Clearside Biomedical, Affibody, Eyevensys, <\/b>among others.<\/p>\n Autoimmune Uveitis Market<\/a><\/b><\/p>\n Autoimmune Uveitis Market Insights, Epidemiology, and Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key autoimmune uveitis\u00a0companies, including Tarsier Pharma, Eli Lilly and Company, Oculis Pharma, Eyevensys, Priovant Therapeutics, Inc.,<\/b> among others.<\/p>\n Anterior Uveitis Market<\/a><\/b><\/p>\n Anterior Uveitis Market Insights, Epidemiology, and Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key anterior uveitis companies, including Novartis AG, Santen Pharmaceutical Co., Ltd; AbbVie Inc., Eyegate Pharmaceuticals, Inc., Clearside Biomedical, Inc., Aldeyra Therapeutics, Inc.,<\/b> among others.<\/p>\n About\u00a0DelveInsight<\/b><\/p>\n DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve.<\/b><\/p>\n Contact Us:\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
<\/b>Shruti Thakur
[email\u00a0protected]<\/a> \u00a0
+14699457679<\/p>\n
![\"\"](\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO80680&Transmission_Id=202505061731PR_NEWS_USPR_____IO80680&DateId=20250506\")
<\/p>\n","protected":false},"excerpt":{"rendered":"YUTIQ addresses a significant unmet need in the treatment of chronic non-infectious uveitis affecting the posterior segment of…\n","protected":false},"author":2,"featured_media":39492,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3091],"tags":[51,22427,22428,2441,16,15],"class_list":{"0":"post-80236","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-business","9":"tag-delveinsight-business-research","10":"tag-llp","11":"tag-markets","12":"tag-uk","13":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114463180317998179","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/80236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=80236"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/80236\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/39492"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=80236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=80236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=80236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}